Truist Securities Upgrades Evolent Health to Buy, Raises Price Target to $33
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has upgraded Evolent Health (NYSE:EVH) from Hold to Buy and raised the price target from $28 to $33.
August 09, 2024 | 9:50 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has upgraded Evolent Health from Hold to Buy and increased the price target from $28 to $33.
The upgrade from Hold to Buy and the increased price target from $28 to $33 by Truist Securities is likely to positively impact Evolent Health's stock price in the short term as it reflects increased confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100